UNH — UnitedHealth Group Incorporated

The Q2 2026 earnings beat and full-year EPS guidance raise to $19.50-$20.00 are clear positives, and the MCR improvement from 89.4% to 86.7% shows margin discipline. Offsetting that, UNH shares were down 1.5% on the date, sit below their 20- and 50-day moving averages, and the market remains wary of Medicare Advantage/ACA membership exits, political scrutiny, and ongoing regulatory investigations.

Revenue growth has deliberately flattened: Q2 2026 revenue of $112.0B was up only 0.4% YoY, versus double-digit YoY growth in 2025, because UNH is exiting roughly 500k ACA and 1.1M Medicare Advantage members. Profitability is inflecting off a 2025 trough: Q2 2026 operating margin was roughly 7.1% versus 4.6% in Q2 2025, and Q1 2026 operating margin was 8.0%. The trailing TTM numbers are distorted by Q4 2025's near-zero net income and Q3 2025's weak quarter; those look like one-off/transitory depression rather than a structural collapse. Reported EPS by quarter swings sharply (6.24, 5.83, -1.53, 4.54, 6.51, 5.98, 6.85, 3.74, 2.59, 0.011, 6.90, 6.05), so the clean read is a margin recovery underway, but not yet sustained long enough to call a strong growth reacceleration.

As of 2026-08-27, UNH is not expensive. TTM P/E is 25.4x versus a 5-year average of 26.3x, and the forward P/E is roughly 20.0x using consensus next-year EPS of $19.76. Price-to-sales is 0.80x versus a 5-year average of 1.27x. The PEG ratio is uninformative because TTM earnings are depressed by one-offs. A 2.18% dividend yield and $20.0B of operating cash flow in H1 2026 add support. The market is granting little credit for the earnings recovery, largely due to regulatory and political overhang.

Price is lagging the earnings recovery. The consensus EPS estimate jumps from $15.59 TTM to $19.76 next year, yet the stock trades near $395, far below the 52-week high of $461.62. In other words, the market is not paying up for the improvement; it is discounting the membership shrinkage and regulatory risk. If UNH hits its raised guidance and margins hold, modest multiple reversion to 23-24x forward earnings implies meaningful upside. If the MCR improvement fades, the current 20x forward multiple gives only a modest downside cushion.

As of 2026-08-27, RSI is 43.65, price is 1.5% below the 20-day SMA and 4.3% below the 50-day SMA, but 13.1% above the 200-day SMA. That is a neutral-to-soft momentum picture: the stock is consolidating after recovering far from the $255.97 52-week low, with the longer-term trend still intact above the 200-day. For entry timing, there is no oversold bounce signal yet; a reclaim of the 20/50-day averages would be a more constructive trigger.

• Interest rates: a still-elevated rate environment rewards UNH's strong cash generation and balance sheet, supporting dividend and buyback capacity.
• Healthcare cost inflation/utilization: sticky medical cost trends are the biggest near-term margin variable; Q2 2026's improved MCR shows pricing discipline working.
• Medicare Advantage reimbursement and prior-authorization regulatory policy: government rate-setting and compliance mandates directly affect revenue and margin.
• Political and regulatory scrutiny of vertical integration across UnitedHealthcare and Optum, which caps the multiple even when financials improve.
• ACA/individual market churn: deliberate exits from unprofitable membership reduce top-line growth but should improve earnings quality.

• Q3 2026 earnings in mid-October, with focus on MCR, membership attrition, and Optum's operating earnings trajectory.
• Medicare Advantage rate announcements or regulatory/policy updates from Washington that could reset margin expectations.
• AI-driven prior-authorization reductions and operational cost initiatives delivering visible margin gains.
• Progress resolving or containing regulatory investigations, which would remove a sentiment overhang.

• Regulatory investigations into Medicare billing, tax matters, and vertical-integration practices could lead to fines, mandates, or structural changes.
• Membership shrinkage—1.1M Medicare Advantage and 500k ACA members—could signal weaker competitive positioning and keep revenue flat or declining.
• Medical cost/utilization could re-accelerate, reversing the MCR improvement and the earnings recovery.
• Legal/political overhang from the December 2024 killing of Brian Thompson and broader anti-managed-care sentiment remains a persistent sentiment risk.

UNH is a high-quality healthcare franchise going through a deliberate, margin-first transition. The Q2 2026 beat, improved MCR, raised guidance, and discounted forward P/E make it a reasonable holding, but the flat revenue trajectory and unresolved regulatory risks mean it is not a high-conviction buy. As of 2026-08-27, it is a fairly valued business with a credible earnings recovery underway.

Calculated by applying a 23.0x forward P/E multiple to consensus next-fiscal-year EPS of $19.76, with the multiple set at roughly a 12% discount to UNH's 5-year average P/E of 26.33x to reflect flat revenue, regulatory overhang, and the still-early margin recovery. This yields $454.48.